1.
Fang C, Lee KK, Nietupski R, et al. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. Bioorg Med Chem Lett. 2018;28(22):3529-3533. doi:10.1016/j.bmcl.2018.09.037.
1.
Naryshkin NA, Weetall M, Dakka A, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688-93. doi:10.1126/science.1250127.
1.
Zhang W, Lun S, Wang S-H, et al. Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. J Med Chem. 2018;61(3):791-803. doi:10.1021/acs.jmedchem.7b01319.
1.
Stanley SA, Kawate T, Iwase N, et al. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc Natl Acad Sci U S A. 2013;110(28):11565-70. doi:10.1073/pnas.1302114110.
1.
Kawate T, Iwase N, Shimizu M, et al. Synthesis and structure-activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32. Bioorg Med Chem Lett. 2013;23(22):6052-9. doi:10.1016/j.bmcl.2013.09.035.